Delving into the Latest Updates on Metformin Hydrochloride with Synapse

Overview

Basic Info

SummaryMetformin Hydrochloride, sold under the trade name GLUCOPHAGE, is a medication used in the treatment of type 2 diabetes mellitus. It was first approved in France in 1957 and is now manufactured by Bristol Myers Squibb Co. GLUCOPHAGE works by activating PRKAB1, which helps to improve glycemic control in both adult and pediatric patients aged 10 years and older, when used in combination with diet and exercise. This medication is a biguanide, and it is commonly used as an adjunct therapy to help manage blood sugar levels in individuals with type 2 diabetes.

Drug Type

Small molecule drug

Synonyms

Meiformin Hydrochloride, Metformin hydrochloride (JP17/USP), Metformin Hydrochlorride

+ [67]

Target

PRKAB1

Action

activators

Mechanism

PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators)

Therapeutic Areas

Endocrinology and Metabolic DiseaseNeoplasmsImmune System Diseases+ [11]

Active Indication

Diabetes Mellitus, Type 2Invasive Mammary CarcinomaChronic Disease+ [51]

Inactive Indication

Acinar Cell CarcinomaAcquired Immunodeficiency SyndromeAdenocarcinoma of large intestine+ [73]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Zhengzhou University Hospital

University of California, Davis

Alliance Foundation Trials LLC

+ [28]

Inactive Organization

Bristol Myers Squibb Co.

Amylin Pharmaceuticals, Inc.Merck KGaA

+ [27]

License Organization

Merck KGaA

The Fox Chase Cancer Center

Sylvester Comprehensive Cancer Center

+ [3]

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1992),

Diabetes Mellitus, Type 2

RegulationPriority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC4H12ClN5

InChIKeyOETHQSJEHLVLGH-UHFFFAOYSA-N

CAS Registry1115-70-4

Phase III, Adaptive, Multicenter, Randomized, Superiority, Double-Dummy, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor and a Thiazolidinedione in the Treatment of Type 2 Diabetes Mellitus, Compared to Monotherapy, in Patients Treated With Metformin

This clinical trial is studying whether combining two commonly used diabetes medications into a single pill works better than taking them separately for people with type 2 diabetes who are already on metformin. Both medications work in different ways to lower blood sugar - one helps remove excess sugar through urine while the other helps the body use insulin better.
The study has two main goals:
To see if the combined pill controls blood sugar more effectively than either medication alone
To check if combining them reduces common side effects like weight gain and swelling that can occur with one of the medications
Participants will be randomly assigned to one of three groups:
The new combination pill
One of the standard diabetes medications alone
The other standard diabetes medication alone
All participants will take their assigned treatment daily and attend regular clinic visits for monitoring. Doctors will track blood sugar control, weight changes, and any side effects throughout the study period.
This research could lead to a simpler treatment option that combines the benefits of both medications while potentially minimizing side effects. For people with diabetes who often need multiple medications, a combined pill might make treatment easier to manage while providing better blood sugar control.

Start Date01 Sep 2026

Sponsor / Collaborator

Eurofarma Laboratórios SA

NCT07300059

/ Not yet recruitingPhase 1

Short-Term Glycemic Effects of Two Concentrations of Liquid Metformin Versus Standard Metformin Tablets in Healthy Adults

This is an open-label, randomized study evaluating the short-term glycemic effects of two concentrations of liquid metformin formulations (100 mg/mL and 250 mg/mL) compared with standard immediate-release metformin tablets in healthy adult subjects. Participants will receive single or short-term doses of study treatments in a randomized sequence. Blood glucose measurements and other glycemic indicators will be collected to assess short-term pharmacodynamic effects. Safety and tolerability will also be monitored.

Start Date15 Jul 2026

Sponsor / Collaborator

Aspargo Labs, Inc.

100 Clinical Results associated with Metformin Hydrochloride

Login to view more data

100 Translational Medicine associated with Metformin Hydrochloride

Login to view more data

100 Patents (Medical) associated with Metformin Hydrochloride

Login to view more data

17,791

Literatures (Medical) associated with Metformin Hydrochloride

02 Jan 2026·DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Bioequivalence and pharmacokinetic prediction of oral marketed metformin extended-release tablets in Saudi Arabia

Article

Author: Alomary, Abdulaziz Abdulrrahman ; Aljutyali, Abdullah S. ; Alwadi, Aiman Y. ; Amin, Mohammed A. ; Ameer, Omar Z. ; Alrashidi, Talal S. ; Abdellatif, Ahmed A. H. ; Maswadeh, Hamzah M. ; Ibrahim, Mohamed A.

OBJECTIVE:

The Saudi market offers dosages of metformin that have varying release rates and can lead to different pharmacological reactions. Studying formulation bioequivalences helps patients choose the optimum medicine without affecting pharmacological responses.

SIGNIFICANCE:

This study affects patient care clinically, which can improve Saudi diabetes management by improving efficacy, safety, adherence, access, and cultural relevance.

METHOD:

The bioequivalence and pharmacokinetic parameters were studied using the convolution method. Similarity factor f₁ and different factors f₂ of different types of metformin tablets were calculated. Furthermore, the pharmacokinetic parameters were estimated using the convolution method.

RESULTS:

At pH = 6.8 (phosphate buffer) and 50 rpm, 100% of metformin was released within 2 h. While, after two hours in HCl at pH = 1.1 followed by five hours in phosphate buffer at pH = 6.8, 100% of the medication was released after 7 h. The release kinetics showed zero-order kinetics with r² = 0.961 for Formit^® and 0.971 for Glucophage^®, while the release mechanism showed that it follows the Higuchi equation with r² = 0.974 for Formit^® and 0.971 for Glucophage^®, respectively, indicating that the mechanism of drug release was controlled by diffusion. The two brands were lyo-equivalent, with a similarity factor and difference factor equal to 59.36 and 7.26, respectively.

CONCLUSION:

The convolution approach indicated that Glucophage^® and Formit^® have bioequivalent C_max of 601 and 592 ng/ml, respectively. The two products had the same projected T_max of 2.0 h and a modest AUC_∞ differential that did not violate the FDA's 80-125% limit.

02 Jan 2026·Expert Opinion On Drug Safety

Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases

Article

Author: El-Tanani, Mohamed ; Sharma, Shrestha ; Rabbani, Syed Arman ; Dubey, Harikesh ; Khurana, Atul ; Sridhar, Sathvik B. ; Arora, Mandeep Kumar

BACKGROUND:

This study aimed to provide an overview of gastrointestinal (GI) adverse events associated with immune checkpoint inhibitors (ICIs) using two pharmacovigilance databases, EudraVigilance and VigiAccess.

RESEARCH DESIGN AND METHODS:

Data was collected from the date of ICI's marketing authorization until 30 November 2023. Reporting odds ratio (ROR) was used as a measure of ADR reporting disproportionality for signal detection.

RESULTS:

Overall, across both databases, EudraVigilance and VigiAccess, a total of 76,606 ADR reports were analyzed. In EudraVigilance, colitis (12,581) and diarrhea (12,108) were the most reported GI adverse events, with similar findings in VigiAccess. Furthermore, in both databases, the most ADR reports were associated with nivolumab and pembrolizumab. Durvalumab (ROR: 3.96, 95%CI :3.65-4.28), ipilimumab (ROR: 1.95, 95%CI: 1.89-2.01), nivolumab (ROR: 1.05, 95%CI: 1.02-1.07), and atezolizumab (ROR: 1.04, 95%CI: 1.01-1.07) demonstrated higher risks of GI events compared to other ICIs. EudraVigilance analysis identified dysphagia, ascites, hematochezia, and gastroesophageal reflux disease as potential signals associated with ICI therapy. Majority of ADR reports (87.2%) comprised serious GI adverse events, a portion of which was associated with fatal outcomes (14.5%). Atezolizumab (14.9%) and pembrolizumab (11.9%) were linked to a higher incidence of fatal outcomes compared to other ICIs.

CONCLUSION:

The differential risk profiles of ICIs-associated-GI adverse events underscore the importance of personalized therapy in oncology.

01 Jan 2026·Cancer treatment and research communications

Pro-apoptotic effects of metformin and cisplatin in non-small cell Lung Cancer: Modulation of apoptosis-related genes and LncRNAs

Article

Author: Soleimanifar, Fatemeh ; Ghayoumi, Romina ; Haddad Kashani, Hamed ; Attar, Elmira ; Etesami, Seyed-Alireza ; Sadeghi, Nazanin

BACKGROUND:

Lung cancer is a leading cause of cancer-related mortality. While cisplatin is a cornerstone of chemotherapy, metformin (Glucophage) has shown anti-cancer potential. This study investigated the effects of cisplatin and metformin (Glucophage) on non-small cell lung cancer (NSCLC) cells, focusing on their combined impact on apoptosis-related genes and lncRNAs.

METHODS:

The A549 (NSCLC) and MRC5 (normal fibroblast) cell lines were treated with cisplatin, metformin (Glucophage), or a combination thereof. Cell viability was assessed by MTT assay, and apoptosis was quantified by flow cytometry. Expression of Bax, Bcl-2, Caspase 3, PVT1, and MEG3 was analyzed by qRT-PCR.

RESULTS:

Both cisplatin and metformin (Glucophage) individually reduced A549 cell viability in a dose-dependent manner. Combination Index (CI) analysis revealed an additive interaction (CI = 0.935) between the two agents. This combination was associated with an upregulation of pro-apoptotic Bax and lncRNA MEG3, and a downregulation of anti-apoptotic Bcl-2 and oncogenic lncRNA PVT1.

CONCLUSION:

The combination of cisplatin and metformin (Glucophage) exerts an additive cytotoxic effect and induces apoptosis in NSCLC cells in vitro. This effect is associated with a favorable modulation of key apoptosis-regulating genes and lncRNAs. These findings provide a strong rationale for further mechanistic and preclinical investigation of this combination therapy for lung cancer.

410

News (Medical) associated with Metformin Hydrochloride

28 Jan 2026

·www.prnewswire.com

Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More

Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease treatment. Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced on January 28 that it has signed an exclusive distribution agreement with Mexican pharmaceutical company Laboratorios Sanfer for efpeglenatide, its GLP-1 obesity therapy, as well as the Dapalon Family, Hanmi's flagship diabetes treatment portfolio (Dapalon Tab. and Dapalon Duo SR Tab.). Under the agreement, Hanmi will supply efpeglenatide and the Dapalon Family, while Laboratorios Sanfer will be responsible for regulatory approval, marketing, distribution, and sales within Mexico. Mexico is one of the countries with the highest obesity rates globally, with obesity prevalence reaching 36.86%, while diabetes prevalence stands at 16.4%.[1] As demand in the market extends beyond weight loss and maintenance therapy to include blood glucose management, the agreement reflects confidence in efpeglenatide's global scalability and strategic value. Founded in 1941, Sanfer is Mexico's largest privately held pharmaceutical company. Leveraging its extensive sales and distribution network across Latin America and its in-house R&D capabilities, Sanfer has established itself as a leading pharmaceutical company in the region. The company operates in more than 20 countries across Latin America as well as in the United States and recently strengthened its position as Mexico's largest biopharmaceutical company through the acquisition of Probiomed. The partnership is expected to gradually expand collaboration across efpeglenatide and other metabolic disease treatments, including additional product launches and joint marketing strategies over the mid- to long term. Ricardo Amtmann, CEO of Sanfer, stated, "As a leading pharmaceutical company in Mexico and Latin America, our vision is to improve patients' lives through innovative, high-quality products. With healthcare costs accounting for 34.6% of household spending in Mexico, improving accessibility to innovative treatments is critical.[2] Hanmi's efpeglenatide and diabetes treatment portfolio meet these needs." He added, "Through this partnership, we aim to contribute to addressing the rapidly growing challenges of obesity and diabetes in Mexico." Jae-hyun Park, CEO of Hanmi Pharmaceutical, said, "This agreement marks an important milestone that demonstrates Hanmi's formulation capabilities and R&D competitiveness on the global stage. As the Mexican government places greater emphasis on standardizing healthcare services and strengthening the management of chronic diseases, we find it especially meaningful that Hanmi's independently developed, Korea's first GLP-1–based obesity and metabolic disease treatment, together with our innovative diabetes treatment portfolio, will be able to contribute to improving the health of the Mexican population." Meanwhile, Hanmi completed its regulatory application for efpeglenatide to the Ministry of Food and Drug Safety on December 17, 2025. In September 2025, the company also submitted an IND for a Phase 3 clinical trial evaluating combination therapy with SGLT-2 inhibitors and metformin, which was approved on January 21, 2026. Hanmi is pursuing an expansion of efpeglenatide's indications from obesity into diabetes, with obesity approval targeted for the second half of 2026 and an additional diabetes indication planned for 2028. Contact info: Official Websites: , [email protected], +82-02-410-0467 SOURCE Hanmi Pharmaceutical 21% more press release views with Request a Demo

AcquisitionPhase 3

19 Jan 2026

·www.einpresswire.com

Serpin Pharma's Shareholders Approve new BOD -Distinguished Leaders in Medicine, Biotechnology, and Strategic Finance

This board strengthens Serpin Pharma’s ability to advance innovative immune‑modulating therapeutics and expand our strategic partnerships in 2026 and beyond. SP16 is a clinically validated, collaborator‑endorsed asset with transformative platform combating inflammation. SP16 is a bio‑superior alternative to the A1ATD drug recently acquired by Sanofi.” — Dr. Alexander Fleming MANASSAS, VA, UNITED STATES, January 19, 2026 / EINPresswire.com / -- Serpin Pharma Inc. Announces Election of New Board of Directors Shareholders Approve Distinguished Leaders in Medicine, Biotechnology, and Strategic Finance Serpin Pharma Inc., a clinical‑stage biotechnology company developing immune‑modulating therapeutics, today announced that shareholders have elected a new Board of Directors at the Company’s Annual Meeting held on December 29, 2025. The newly elected board brings together internationally recognized experts in drug development, regulatory science, academic medicine, and financial strategy to support Serpin Pharma’s next phase of growth. “The election of this board marks a significant milestone for Serpin Pharma,” said Dr. Cohava Gelber, Founder, CEO, and Executive Chairperson. “Their collective expertise strengthens our ability to advance innovative therapies, expand strategic partnerships, and deliver meaningful impact for patients.” Newly Elected Directors Dr. Denise Barbut, MD, FRCP, FCPP A physician, scientist, and serial entrepreneur, Dr. Barbut has founded and led multiple medtech and biotech companies and raised more than $300 million to advance breakthrough therapies. A former Professor of Neurology at Weill‑Cornell Medical College and Chief of the Neurovascular Division, she holds approximately 300 issued patents and is widely recognized for her contributions to cerebral protection, therapeutics, and regenerative medicine. Dr. G. Alexander Fleming, MD Dr. Fleming is a globally respected regulatory expert and former senior official at the U.S. Food and Drug Administration. During his FDA tenure, he led approvals for metformin, the first statin, insulin analogs, PPAR‑agonists, and multiple growth hormone indications. He is Executive Chairman of Kinexum and President of the Kitalys Institute, and continues to shape international regulatory policy and clinical development standards. Dr. Lawrence Steinman, MD A leading physician‑scientist and Professor of Neurology and Neurological Sciences at Stanford University, Dr. Steinman is known for pioneering work in autoimmune and neuroinflammatory diseases. His discoveries contributed to therapies now used worldwide for multiple sclerosis and Crohn’s disease. He is an elected member of the National Academy of Sciences and the National Academy of Medicine and has co‑founded several biotechnology companies. William B. Johns, MBA Mr. Johns is a seasoned executive with deep experience in global finance, capital markets, and healthcare information technology. As former CEO of Healthcare Capital Corp., he led strategic transactions in the healthcare IT sector. He currently advises private investors and family offices through W. Johns Associates LLC, providing governance and investment strategy expertise. Dr. Cohava Gelber, PhD, MBA Founder, CEO, and Executive Chairperson of Serpin Pharma, Dr. Gelber brings more than 25 years of leadership in drug discovery, translational research, and biotechnology management. She has held senior roles at Duke University, ImmuLogic, ATCC, and MannKind Corporation, and has secured more than $500 million in grants and contracts. She continues to guide Serpin Pharma’s scientific and strategic direction. About Serpin Pharma Inc. Serpin Pharma Inc. is a clinical biotechnology company developing SP16, a powerful, first‑in‑class platform that activates the body’s own inflammation‑resolving pathways through precise LRP1 targeting, delivering potent efficacy without immune suppression. Its 300‑fold enhanced activity over AAT, exceptional safety profile, and broad clinical validation position it as a transformative engine for multiple high‑value inflammatory and autoimmune indications. The company is committed to advancing transformative treatments for inflammatory, autoimmune, and degenerative diseases through rigorous science, strategic collaboration, and patient‑focused innovation. DR. Cohava Gelber Serpin Pharma +1 703-343-3258 cgelber@serpinpharma.com Visit us on social media: LinkedIn X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Executive ChangeDrug Approval

12 Jan 2026

·www.biospace.com

Health Canada approves RYBELSUS® (semaglutide tablets) to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes

RYBELSUS ® (semaglutide tablets) is the first glucagon-like peptide-1 ( GLP-1 ) approved in Canada to reduce the risk of major adverse cardiovascular events (MACE). 1 RYBELSUS ® (semaglutide tablets) is approved to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or are at high risk for these events. 1,2 The indication expansion is based on positive outcomes observed in the cardiovascular outcomes (SOUL) trial data, which demonstrated that RYBELSUS ® decreased the risk of major adverse cardiovascular events. 1 Cardiovascular disease is the second-leading cause of death in Canada. 3 MISSISSAUGA, ON , Jan. 12, 2026 /CNW/ - Novo Nordisk announced today that Health Canada has approved RYBELSUS ® (semaglutide tablets) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or are at high risk for these events. 1, 2 In Canada, cardiovascular disease remains a public health challenge, with heart disease as the second leading cause of death and a leading cause of hospitalization. 4 It's estimated that 9 in 10 Canadians have at least one risk factor for stroke, heart disease, or vascular cognitive impairment including: sex, age, diabetes, family history and Indigenous, South Asian and African family heritage. 5 Health Canada's approval of this indication is based on the results of the SOUL trial. 2 Trial results confirmed that the risk of a major adverse cardiovascular event (MACE) decreased with the use of RYBELSUS ® as compared to a placebo, when used concomitantly with standard of care treatments for diabetes and cardiovascular disease. 1 "This approval marks an important milestone for type 2 diabetes patients in Canada, who are at higher risk of cardiovascular events due to the chronic disease," says Vince Lamanna, President, Novo Nordisk Canada Inc. "RYBELSUS is the first and only approved GLP‑1 in pill form in Canada that improves glycemic control and offers cardiovascular protection." About the SOUL Trial 2 SOUL was a randomized, double-blind, parallel-group, placebo-controlled trial evaluating the effect of RYBELSUS ® on patients who were 50 years of age or older with type 2 diabetes mellitus and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD). In total, 9650 patients were randomised to receive either RYBELSUS ® 14 mg or the placebo daily. The primary endpoint, MACE, was the time to first occurrence of a three-part composite outcome which included cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. About RYBELSUS ® (semaglutide tablets) 1 RYBELSUS ® is the first and only glucagon-like peptide-1 ( GLP-1 ) analogue available in a tablet in Canada to treat type 2 diabetes mellitus and is indicated as a monotherapy when metformin is considered inappropriate due to intolerance or contraindications. Health Canada approved RYBELSUS ® in April 2020 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.ca , Facebook , Instagram , X , LinkedIn and YouTube . References _________________________________________ 1 Novo Nordisk Canada Inc. (2025, December 31, 2025). RYBELSUS ® (semaglutide tablets) Product Monograph 2 Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. McGuire DK, Marx N, Mulvagh SL, et al .; SOUL Study Group. N Engl J Med . Published online March 29, 2025 3 Increasing Prevalence and Incidence of Atherosclerotic Cardiovascular Disease in Adult Patients in Ontario, Canada From 2002 to 2018 Mackinnon, Erin S . et al . CJC Open, Volume 4, Issue 2, 206 – 213. (21)00272-9/fulltext 4 Heart disease in Canada: Highlights from the Canadian Chronic Disease Surveillance System. The Burden at a Glance. Government of Canada. 5 Heart and Stroke Foundation. Working with your doctor. SOURCE Novo Nordisk Canada Inc.

Drug ApprovalClinical ResultAHA

100 Deals associated with Metformin Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00944	Metformin Hydrochloride	A10BA02	DBSALT000114

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	United States	Andrx Labs LLC	27 Apr 2004
Diabetes Mellitus, Type 2	China	Ankang Zhengda Pharmaceutical Co. Ltd.	01 Jan 1992

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Invasive Mammary Carcinoma	Phase 3	United States	City of Hope National Medical Center	16 Dec 2024
Chronic Disease	Phase 3	United States	Oklahoma Medical Research Foundation	29 Jul 2020
Acquired Immunodeficiency Syndrome	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Feb 2019
Aortic Aneurysm, Abdominal	Phase 3	Austria	Merck Serono GmbH	26 Sep 2018
Fragile X Syndrome	Phase 3	United States	University of California, Davis	30 Apr 2018
Fragile X Syndrome	Phase 3	Canada	University of California, Davis	30 Apr 2018
Metabolic Syndrome	Phase 3	United States	Rutgers State University of New Jersey	07 Aug 2017
Atypical hyperplasia	Phase 3	United States	Alliance Foundation Trials LLC	23 Nov 2015
Breast Cancer	Phase 3	United States	Alliance Foundation Trials LLC	23 Nov 2015
Breast hyperplasia	Phase 3	United States	Alliance Foundation Trials LLC	23 Nov 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05741372 (CTgov)	Not Applicable	Liver Cirrhosis	28	Rosuvastatin+digoxin+Metformin hydrochlorid+furosemide (Group 1: Healthy Participants)	pqskxbnxaf(hsccslreqg) = jrboezqxkf qloeedecwp (gouvjgwgux, NA) View more	-	13 Jan 2026
				Rosuvastatin+digoxin+Metformin hydrochlorid+furosemide (Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated))	pqskxbnxaf(hsccslreqg) = fjjiolyafk qloeedecwp (gouvjgwgux, NA) View more
NCT06504862 (CTgov)	Phase 1	-	32	Dabigatran-etexilate (Dabigatran-etexilate (R))	tdsshylwix(tfyvwgqzcn) = ffkfnrejvf crmyzrtjzj (uiulkuhwly, NA) View more	-	09 Jan 2026
				Zongertinib+dabigatran-etexilate (T (Zongertinib and dabigatran-etexilate (T))	tdsshylwix(tfyvwgqzcn) = ljumtvxrwu crmyzrtjzj (uiulkuhwly, NA) View more
NCT01666171 (Alliance A211201, SABCS2025)	Phase 2	Early Stage Breast Carcinoma estrogen receptor negative (ER-) \| HER2+	146	Metformin	atdblaomer(ctvdizdguq): P-Value = 0.58 View more	Negative	11 Dec 2025
				Placebo
NCT03109847 (CTgov)	Phase 2	Differentiated Thyroid Gland Carcinoma \| Thyroid Dysgenesis	13	Radioactive Iodine+Metformin Hydrochloride (Arm I (metformin hydrochloride))	tzwccncwxc(dydxiqryka) = cjtqwxqqbx mlenzzpigi (wvgarwjfpc, mptfgjtfwz - guevyzhnsa) View more	-	11 Dec 2025
				Radioactive Iodine (Arm II (placebo))	tzwccncwxc(dydxiqryka) = njqalqgveo mlenzzpigi (wvgarwjfpc, kryxehtlwu - mzjcrhwfgv) View more
NCT03229057 (COMET-PCOS, Pubmed \| PLoS Med)	Phase 3	-	240	Low-dose COCPs (20 μg ethinyl estradiol/0.15 mg desogestrol)	ehhbgjcwic(avnzxaduzb) = piierkoken kmogtuhiax (jhawtsoucz )	Positive	08 Dec 2025
				Metformin XR (2,000 mg)	ehhbgjcwic(avnzxaduzb) = pwrhncsipl kmogtuhiax (jhawtsoucz )
NCT05064488 (CTgov)	Phase 1	-	40	rosuvastatin+digoxin+metformin (Part 1: Cocktail)	vvakfvwcvf(poiwcbybwu) = qweqmuanig jhivwhscha (jwyegzrfnx, 21.5) View more	-	05 Dec 2025
				Evobrutinib (Part 1: Evobrutinib + Cocktail)	vvakfvwcvf(poiwcbybwu) = vggggahkvw jhivwhscha (jwyegzrfnx, 23.7) View more
NCT05120505 (Pubmed \| Mol Autism)	Phase 2	Fragile X Syndrome	30	Metformin	rbpqveczne(kopqtxqeyw) = rqantrreee luglnskwrx (szmfqbwvon, 15.31) View more	Positive	25 Nov 2025
				Placebo	rbpqveczne(kopqtxqeyw) = koptrriewb luglnskwrx (szmfqbwvon, 23.67) View more
NCT04885530 (ACTIV-6, CTgov)	Phase 3	COVID-19	10,956	Ivermectin (Arm A - Ivermectin 400)	cesqnrcdot = mchgjpngva bnadncqnnr (zbhjhzqfdn, ggddlhzola - xtsaovknvd) View more	-	17 Nov 2025
				Fluvoxamine (Arm B - Fluvoxamine)	cesqnrcdot = lxxyoenvuk bnadncqnnr (zbhjhzqfdn, qeqdfxpcod - llziyngsel) View more
NCT03355469 (CTgov)	Phase 2/3	Metabolic Syndrome	91	Placebo (LoEx With Placebo)	kzdslawfzy(efhvoufwcj) = dodmqkmwgr bsntdzbxhk (xrfpgffbsh, slslvrczll - ekbzkrkmaq) View more	-	22 Sep 2025
				High Intensity Exercise (HiEx With Placebo)	kzdslawfzy(efhvoufwcj) = wvqcklvhes bsntdzbxhk (xrfpgffbsh, qfsovfrpce - rvtdeuqkis) View more
NCT03765359 (Pubmed \| Diabetes Metab Res Rev)	Phase 4	Diabetes Mellitus, Type 1	101	Metformin (Type 1 Diabetes)	ufzrxtulkz(gbdsxwsxij): P-Value = 0.193 View more	Positive	01 Sep 2025
				Placebo (Type 1 Diabetes)